READ-ONLY DIGITIZATION RESULT
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
Blood · 2026-Apr-09 · PMID 41490515
Panel C提取完成待 EXE 对齐验证
Relapse-free survival (RFS)
Figure 2. Primary and secondary end points. (A) EFS in the ITT population. In this EFS analysis, molecular persistence or molecular relapse are considered as treatment failure. There was no statistically significant difference in EFS between treatment arms (HR, 0.92; 95% CI, 0.63-1.33; stratified log-rank test, P = .66). (B) OS. There was no statistically significant difference in OS between treatment arms (HR, 0.93; 95% CI, 0.53-1.63; stratified log-rank test, P = .79). (C) RFS. There was no statistically significant difference in RFS between treatment arms (HR, 0.82; 95% CI, 0.55-1.21; stratified log-rank test, P = .31).
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T16:22:35+00:00 |